[{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"Rubedo Life Sciences","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Khosla Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Rubedo Life Sciences \/ Khosla Ventures"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"RBO-0618","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Rubedo Life Sciences \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubedo Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"RLS-1496","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Khosla Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Life Sciences \/ Khosla Ventures"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Beiersdorf AG","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"RLS-1496","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Beiersdorf AG","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Life Sciences \/ Beiersdorf AG"}]

Find Clinical Drug Pipeline Developments & Deals by Rubedo Life Sciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BMWS24
                          Not Confirmed
                          BMWS24
                          Not Confirmed

                          Details : The funding will be utilized to progress the company’s primary candidate, RLS-1496, for treating patients with atopic dermatitis and chronic psoriasis.

                          Brand Name : RLS-1496

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 22, 2024

                          Lead Product(s) : RLS-1496

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Sponsor : Khosla Ventures

                          Deal Size : $40.0 million

                          Deal Type : Series A Financing

                          blank

                          02

                          BMWS24
                          Not Confirmed
                          BMWS24
                          Not Confirmed

                          Details : The financing will be utilized to fund the progress of the company’s primary candidate, RLS-1496, for treating patients with atopic dermatitis and chronic psoriasis.

                          Brand Name : RLS-1496

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 22, 2024

                          Lead Product(s) : RLS-1496

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Sponsor : Beiersdorf AG

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          BMWS24
                          Not Confirmed
                          BMWS24
                          Not Confirmed

                          Details : Presented in vivo efficacy data for its small molecule therapy engineered via ALEMBIC™ drug discovery platform, targetes senescent cells that drive cellular aging to treat dermatological diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 20, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The funding will support research and development of a pharmacological regenerative treatment of idiopathic pulmonary fibrosis (IPF), RBO-0618, targeting senescent lung stem cells.

                          Brand Name : RBO-0618

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 06, 2023

                          Lead Product(s) : RBO-0618

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Discovery

                          Sponsor : California Institute for Regenerative Medicine

                          Deal Size : $1.4 million

                          Deal Type : Funding

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The funding will be used to advance the company’s lead candidates in respiratory diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 03, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Khosla Ventures

                          Deal Size : $12.0 million

                          Deal Type : Financing

                          blank